LabGenius

London-based LabGenius runs a drug-discovery platform, EVA, that fuses machine learning, robotic automation and synthetic biology to design and optimize complex therapeutic antibodies.

Its focus is selectivity-enhanced antibodies for hard targets like solid tumors, where conventional design struggles. It partners with major pharma, including multiple programs with Sanofi.

It exemplifies the 'lab-in-the-loop' approach, where AI proposes and automated experiments test, around the clock.